The best case scenario is that NNLX made good use of the temporary lift in restrictions and advanced N-Assay viral testing through a corporate partnership.

You're right that there is a larger market for viral testing in general, it actually goes hand in hand with cutting back on antibiotic misuse since many doctors hand out prescriptions for viral infections.

I wouldn't call Ebola nothing. We've contained it pretty well, but the lag time to confirm a diagnosis could make it pretty devastating in cities like NY. The value of a rapid detection test would significantly reduce the speed of spread. The media fear leads to an emphasis on prevention, detection and cure - so if Ebola ever pops back up in the heart of a city with heavy population density, we will be relatively calm knowing that we are prepared.

Also consider that Ebola is far from contained in West Africa, where the real battle and need for rapid detection is. Europe is just a ferry ride away if it were ever to spread across the desert to North Africa.